Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „adalimumab“
Suchtreffer
Begriffe & Kennungen
Hefiya · 4.8 · In controlled Phase 3 studies of adalimumab in patients with rheumatoid arthritis and psoriatic arthritis with
Eintrag öffnenHefiya · 4.8 · In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenHefiya · 4.8 · In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenHefiya · 4.8 · In controlled studies of adalimumab (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg
Eintrag öffnenHefiya · 4.8 · In controlled studies of adalimumab (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg
Eintrag öffnenHefiya · 4.8 · In controlled studies of adalimumab (initial doses of 80 mg at Week 0 followed by 40 mg every other week start
Eintrag öffnenHefiya · 4.8 · In controlled studies of adalimumab (initial doses of 80 mg at Week 0 followed by 40 mg every other week start
Eintrag öffnenHefiya · 4.8 · In the Phase 3 study of adalimumab in patients with paediatric Crohn’s disease which evaluated efficacy and sa
Eintrag öffnenHefiya · 4.8 · In the Phase 3 study of adalimumab in patients with paediatric Crohn’s disease which evaluated efficacy and sa
Eintrag öffnenHefiya · 4.8 · In the controlled Phase 3 study of adalimumab in patients with paediatric ulcerative colitis (N=93) which eval
Eintrag öffnenHefiya · 4.8 · In the controlled Phase 3 study of adalimumab in patients with paediatric ulcerative colitis (N=93) which eval
Eintrag öffnenHefiya · 4.8 · In the pivotal controlled studies in adults and children, 12.9 % of patients treated with adalimumab developed
Eintrag öffnenHefiya · 4.8 · In the pivotal controlled studies in adults and children, 12.9 % of patients treated with adalimumab developed
Eintrag öffnenHefiya · 4.8 · No ALT elevations ≥ 3 x ULN occurred in the Phase 3 study of adalimumab in paediatric patients with plaque pso
Eintrag öffnenHefiya · 4.8 · No ALT elevations ≥ 3 x ULN occurred in the Phase 3 study of adalimumab in paediatric patients with plaque pso
Eintrag öffnenHefiya · 4.8 · Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the im
Eintrag öffnenHefiya · 4.8 · Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the im
Eintrag öffnenHefiya · 4.8 · The incidence of serious infections was 0.04 per patient year in adalimumab-treated patients and 0.03 per pati
Eintrag öffnenHefiya · 4.8 · The safety profile for patients with HS treated with adalimumab weekly was consistent with the known safety pr
Eintrag öffnenHefiya · 4.8 · The safety profile for patients with HS treated with adalimumab weekly was consistent with the known safety pr
Eintrag öffnen